Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology
-$0.25 today
- Market cap
- $1.57B
- Beta
- 1.64
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.00
Volume 2.15M
Average 1.76M
VIR Sales of Investments
Cash received from selling or redeeming investments.
Vir Biotechnology, Inc.NASDAQ: VIR
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments declines year over year
Q1 FY2026 sales of investments of $170.6M fell 43.5% year over year, behind the -26.1% change in trailing-twelve-month sales of investments. Sequentially, it fell 50.3% from the prior quarter. Over 3 fiscal years it compounded at +50.6% a year.
Context
- Sales of investments amounted to 1752.3% of revenue in FY2025, down 590.7 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -43.5% toward the trailing-twelve-month pace of -26.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 1.2B USD
- Year-over-year change
- -30.9%
- 4-year CAGR
- +41.3%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.2B | -30.9% |
| FY2024 | 2024-12-31 | 1.74B | -21.1% |
| FY2023 | 2023-12-31 | 2.2B | +526.6% |
| FY2022 | 2022-12-31 | 351.51M | +16.7% |
| FY2021 | 2021-12-31 | 301.24M | — |
Sales of Investments vs competitors
How VIR compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -26.1% is the 6th highest of 9, against a peer median of -12.7%.
- Sales of investments amounts to 1633.7% of revenue for VIR, versus a peer median of 142.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €10.31B EUR | -19.6% | +189.9% | 389.9% | |
| LTM Sep 2026 | $5.45B USD | -34.0% | +5.7% | 215.6% | |
| LTM Mar 2026 | $1.07B USD | -26.1% | +50.6% | 1633.7% | |
| LTM Mar 2026 | $458.02M USD | -5.9% | — | 76.8% | |
| LTM Jun 2026 | $368.93M USD | +61.7% | +29.8% | 39.2% | |
| LTM Mar 2026 | $366.77M USD | -26.9% | +72.4% | — | |
| LTM Mar 2026 | $287.42M USD | +13.1% | +4.8% | 415.3% | |
| LTM Mar 2026 | $147.6M USD | +8.4% | -0.1% | 207.6% | |
| LTM Mar 2026 | $125.21M USD | -27.8% | +40.5% | 65.4% | |
| LTM Mar 2026 | €1.39M EUR | — | — | 0.9% | |
| Peer median (excluding VIR) | — | -12.7% | +29.8% | 142.2% | |
Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 528.58M | 515.84M | (615.06M) | (521.96M) | (437.99M) |
| Depreciation & Amortization | 5.81M | 6.78M | 19.45M | 14.56M | 21.15M |
| Deferred Income Tax | 15.19M | (15.19M) | (1.06M) | (2.95M) | 0 |
| Stock-Based Compensation | 83.78M | 102.08M | 0 | 78.46M | 49.07M |
| Change in Working Capital | (628.39M) | 665.37M | (304.59M) | (84.01M) | (22.45M) |
| Accounts Receivables | (773.08M) | 770.04M | (565K) | (6.51M) | 0 |
| Inventory | 52.82M | 0 | 0 | 0 | 0 |
| Accounts Payables | (171K) | 797K | 732K | (988K) | 5M |
| Other Working Capital | 92.04M | (105.47M) | (304.76M) | (76.51M) | (27.44M) |
| Other Non-Cash Items | (52.56M) | 388.37M | 122.48M | 69.55M | (1.57M) |
| Operating Cash Flow | (47.59M) | 1.66B | (778.79M) | (446.35M) | (391.78M) |
| Capital Expenditures | (21.82M) | (68.01M) | (21.57M) | (7.3M) | (4.83M) |
| Acquisitions (Net) | 140.81M | 0 | 100K | 3.37M | 253K |
| Purchases of Investments | (420.24M) | (1.48B) | (2.02B) | (1.24B) | (886.33M) |
| Sales of Investments | 301.24M | 351.51M | 2.2B | 1.74B | 1.2B |
| Other Investing Activities | (140.81M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (140.81M) | (1.19B) | 164.73M | 499.37M | 310.37M |
| Debt Repayment | (259K) | (260K) | (287K) | (165K) | (361K) |
| Common Stock Issued | 85.21M | 28.46M | 7.77M | 4.55M | 4.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 15.38M | 6.56M | (100K) | 0 | 0 |
| Financing Cash Flow | 100.33M | 34.76M | 7.38M | 4.39M | 3.79M |
| Effect of Forex Changes | 0 | 0 | 208K | 0 | 0 |
| Net Change in Cash | (88.07M) | 504.55M | (606.47M) | 57.4M | (77.63M) |
| Free Cash Flow | (69.41M) | 1.6B | (800.36M) | (453.65M) | (396.61M) |
Vir Biotechnology, Inc.
NASDAQ:VIR
Intrinsic Alpha fair value
Locked
Current Price
$9.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.